Home/Filings/4/A/0001123292-17-000719
4/A//SEC Filing

Recro Pharma, Inc. 4/A

Accession 0001123292-17-000719

CIK 0001588972operating

Filed

Mar 19, 8:00 PM ET

Accepted

Mar 20, 3:25 PM ET

Size

5.6 KB

Accession

0001123292-17-000719

Insider Transaction Report

Form 4/AAmended
Period: 2017-02-17
Transactions
  • Sale

    Common Stock

    2017-02-17$7.59/sh9,983$75,7912,292,839 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016.
  • [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.45 to $7.84, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
  • [F3]This amendment corrects a previous clerical error to the "Amount of Securities Beneficially Owned Following Reported Transaction" contained in the Form 4 filed on February 21, 2017.

Issuer

Recro Pharma, Inc.

CIK 0001588972

Entity typeoperating
IncorporatedPA

Related Parties

1
  • filerCIK 0001588972

Filing Metadata

Form type
4/A
Filed
Mar 19, 8:00 PM ET
Accepted
Mar 20, 3:25 PM ET
Size
5.6 KB